Market capitalization | $6.63m |
Enterprise Value | $7.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-657.00k |
Free Cash Flow (TTM) Free Cash Flow | $-540.00k |
EPS (TTM) EPS | $-0.25 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -0.65 -0.65 |
2%
2%
|
EBIT (Operating Income) EBIT | -0.66 -0.66 |
1%
1%
|
Net Profit | -1 -1 |
163%
163%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.
Head office | Israel |
CEO | Tomer Izraeli |
Founded | 2005 |
Website | polyrizon-biotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.